Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;1482(1):121-129.
doi: 10.1111/nyas.14511. Epub 2020 Oct 15.

Endoscopic treatments for GERD

Bradley S Kushner  1 , Michael M Awad  1 , Dean J Mikami  2 , Bipan B Chand  3 , Christina J Wai  2 , Kenric M Murayama  2
Affiliations
Review

Endoscopic treatments for GERD

Bradley S Kushner et al. Ann N Y Acad Sci. 2020 Dec.

Abstract

Gastroesophageal reflux disease (GERD) is a condition with increasing prevalence and morbidity in the United States and worldwide. Despite advances in medical and surgical therapy over the last 30 years, gaps remain in the therapeutic profile of options. Flexible upper endoscopy offers the promise of filling in these gaps in a potentially minimally invasive approach. In this concise review, we focus on the plethora of endoluminal therapies available for the treatment of GERD. Therapies discussed include injectable agents, electrical stimulation of the lower esophageal sphincter, antireflux mucosectomy, radiofrequency ablation, and endoscopic suturing devices designed to create a fundoplication. As new endoscopic treatments become available, we come closer to the promise of the incisionless treatment of GERD. The known data surrounding the indications, benefits, and risks of these historical, current, and emerging approaches are reviewed in detail.

Keywords: GERD; emerging technology; endoscopic therapy; flexible endoscopy.

PubMed Disclaimer

References

    1. Cohen, L.B., D.A. Johnson, R.A. Ganz, et al. 2005. Enteryx implantation for GERD: expanded multicenter trial results and interim postapproval follow-up to 24 months. Gastrointest. Endosc. 61: 650-658.
    1. Deviere, J., G. Costamagna, H. Neuhaus, et al. 2005. Nonresorbable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multicenter trial. Gastroenterology 128: 532-540.
    1. Domagk, D., J. Menzel, M. Seidel, et al. 2006. Endoluminal gastroplasty (EndoCinch) versus endoscopic polymer implantation (Enteryx) for treatment of gastroesophageal reflux disease: 6-month results of a prospective, randomized trial. Am. J. Gastroenterol. 101: 422-430.
    1. Fockens, P., L. Cohen, S.A. Edmundowicz, et al. 2010. Prospective randomized controlled trial of an injectable esophageal prosthesis versus a sham procedure for endoscopic treatment of gastroesophageal reflux disease. Surg. Endosc. 24: 1387-1397.
    1. Ganz, R.A., E. Fallon, T. Wittchow & D. Klein. 2009. A new injectable agent for the treatment of GERD: results of the Durasphere pilot trial. Gastrointest. Endosc. 69: 318-323.

MeSH terms

Substances